Lusutrombopag

Lusutrombopag is an oral thrombopoietin receptor agonist (TPO-RA) indicated for the treatment of adult patients with chronic liver disease and thrombocytopenia who are scheduled to undergo surgery.

1. Drug name

1. Generic name: Lusutrombopag

2. Trade name: MULPLETA

2. Indications

It is used to treat thrombocytopenia in adult patients with chronic liver disease, and is suitable for patients who plan to undergo surgery.

3. Specifications and properties of

1. Specifications: 3mg/tablet.

2. Properties: round film-coated tablets.

IV. Main ingredients

1. Active ingredient: Lusutrombopag

2. Excipients: D-mannitol, microcrystalline cellulose, magnesium oxide, sodium lauryl sulfate, hydroxypropyl cellulose, etc.

V. Usage and Dosage

1. Recommended dosage: 3 mg orally, once a day, for 7 consecutive days.

2. Medication timing: Start taking medication 8-14 days before surgery, and perform surgery within 2-8 days after the last dose.

3. Treatment of missed doses: If you miss a dose, you should take it as soon as possible on the same day and resume the normal medication schedule the next day.

6. Dose adjustment

There is no special dosage adjustment instructions. It is limited to a 7-day treatment course and cannot be extended for "normalization of platelet count".

7. Medication Precautions

1. Before and after meals: It can be taken with food or on an empty stomach.

2. Vomiting: If you vomit after taking the medicine, there is no need to take a supplement and continue taking the medicine as originally planned.

3. Monitoring: Platelet count needs to be detected before medication and within 2 days before surgery.

8. Medication for special groups

1. Pregnant women: There is no human data, animal experiments show risks, and the pros and cons need to be weighed.

2. Lactation period: Breastfeeding is prohibited during treatment and within 28 days after the last dose.

3. Children: Safety has not been established.

4. Elderly patients: There is no significant difference from young patients.

9. Adverse reactions

1. The most common: headache (≥3%).

2. Serious risks: thrombosis/thromboembolic events (such as portal vein thrombosis).

10. Contraindications

There are no clear contraindications, but caution needs to be assessed when there is a risk of thrombosis.

11. Drug interactions

1. There is no significant effect when combined with cyclosporine (P-gp/BCRP inhibitor) or multivalent cation-containing antacids.

2. In vitro studies show that the risk of inhibiting CYP enzymes, UGT enzymes and common transporters is low.

12. Storage method

1. Store in original packaging at 20°C-25°C (15°C-30°C allowed).

2. Keep out of reach of children.